Treatment of EVD with T-705 (favipiravir) was associated with prolonged survival and markedly reduced viral load
August 27th, 2016, , , , Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with favipiravir (T-705), Sierra Leone, 2014 Clin Infect Dis. ciw571 first published online August 23, 2016 doi:10.1093/cid/ciw571
“…..Among the 35 patients who finished all designed endpoint observations, the survival rate in T-705 treatment group (64.8%, 11/17) was higher than that of control group (27.8%, 5/18). Furthermore, the average survival time of the treatment group (46.9±5.6 days) was longer than that of the control group (28.9±4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had over a 100 fold viral load reduction, compared to only 16.7% of patients in the control group. …..”